Jump to content

Uridine triacetate

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 19:59, 22 July 2016 (image, prodrug, categories). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Uridine triacetate
Clinical data
Trade namesVistogard, Xuriden
Routes of
administration
Oral granules
Legal status
Legal status
Pharmacokinetic data
MetabolismPyrimidine catabolic pathway
Onset of actionTmax = 2-3 hours
Elimination half-life2-2.5 hours
ExcretionRenal
Identifiers
DrugBank
CompTox Dashboard (EPA)
ECHA InfoCard100.021.710 Edit this at Wikidata
Chemical and physical data
FormulaC15H18Cl0N2O9S0
Molar mass370.31 g·mol−1

Uridine triacetate is a drug used in the treatment of hereditary orotic aciduria[1] and to treat patients following an overdose of chemotherapy drugs 5-fluorouracil or capecitabine, or in patients exhibiting early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of 5-fluorouracil or capecitabine administration.[2][3]

Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics and it is marketed in USA by BTG. Also, It was granted breakthrough therapy designation by FDA in 2015.

Uridine triacetate is a prodrug of uridine.[4]

References

  1. ^ HIGHLIGHTS OF PRESCRIBING INFORMATION OF XURIDEN
  2. ^ BTG Announces FDA Approval of VISTOGARD® (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine
  3. ^ "FDA Approved Drugs:Uridine Triacetate". FDA. 2015-12-11. Retrieved 2016-04-29.
  4. ^ "Uridine triacetate". DrugBank.